Compare ATNI & EBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATNI | EBS |
|---|---|---|
| Founded | 1987 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 415.7M | 413.3M |
| IPO Year | 1994 | 2006 |
| Metric | ATNI | EBS |
|---|---|---|
| Price | $23.35 | $7.65 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | 75.1K | ★ 978.6K |
| Earning Date | 05-06-2026 | 04-30-2026 |
| Dividend Yield | ★ 4.03% | N/A |
| EPS Growth | 34.29 | ★ 125.83 |
| EPS | N/A | ★ 0.07 |
| Revenue | $727,975,000.00 | ★ $742,900,000.00 |
| Revenue This Year | $3.12 | $1.29 |
| Revenue Next Year | $1.10 | N/A |
| P/E Ratio | ★ N/A | $109.86 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $13.86 | $5.62 |
| 52 Week High | $30.45 | $14.06 |
| Indicator | ATNI | EBS |
|---|---|---|
| Relative Strength Index (RSI) | 38.25 | 42.52 |
| Support Level | $22.76 | N/A |
| Resistance Level | $23.76 | $8.59 |
| Average True Range (ATR) | 1.16 | 0.30 |
| MACD | -0.12 | -0.05 |
| Stochastic Oscillator | 13.50 | 21.60 |
ATN International Inc is a telecommunications and utilities company. The company provides digital infrastructure and communications services with a focus on rural and remote markets in the United States, and internationally, including Bermuda and the Caribbean region. Its operating segments comprise U.S. Telecom and International Telecom. The company earns revenue from its International telecommunication segment.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.